Australia's national zoster vaccination program: Knowledge, attitudes and behaviour of general practitioners.


Journal

Communicable diseases intelligence (2018)
ISSN: 2209-6051
Titre abrégé: Commun Dis Intell (2018)
Pays: Australia
ID NLM: 101735394

Informations de publication

Date de publication:
15 Jul 2020
Historique:
entrez: 16 7 2020
pubmed: 16 7 2020
medline: 16 6 2021
Statut: epublish

Résumé

To assess knowledge, attitudes and behaviour of Australian general practitioners (GPs) regarding herpes zoster vaccination under the National Immunisation Program (NIP) from 2016 for adults aged 70-79 years. National cross-sectional online survey of GPs, October-November 2017. Knowledge, attitudes and behaviour regarding zoster vaccination, including challenges experienced and recommendations for improvement. Of the 1026 GPs who responded (response rate 7.9%), 98.5% were aware that zoster vaccine is NIP-funded for adults aged 70-79 years and 85.4% that it is recommended for age 60-69 years; however, 51.3% incorrectly thought it is routinely recommended for age 50-59 years. A minority (4.6%) incorrectly believed that being immunocompromised is not a contraindication to zoster vaccination and 16.0% that it cannot be co-administered with influenza or pneumococcal vaccine. Almost half (48.9%) rarely or never reported zoster vaccination data to the Australian Immunisation Register (AIR). Challenges perceived included lack of adequate information on vaccine contraindications; efficacy and safety concerns; and difficulty applying age criteria for NIP eligibility in general practice. Respondents indicated a desire for program expansion to include younger and older adult age groups. This Australian GP survey, conducted one year after the introduction of the national zoster vaccination program, identified some knowledge gaps. A repeat survey of GPs is warranted to determine whether these issues persist, particularly regarding contraindication to vaccination for immunocompromised individuals. We encourage all GPs to offer zoster vaccination in line with current Australian evidence-based guidelines, particularly for the NIP-funded 70-79 years cohort; ensuring compliance with relevant contraindications; and reporting to AIR.

Identifiants

pubmed: 32664832
doi: 10.33321/cdi.2020.44.59
doi:

Substances chimiques

Herpes Zoster Vaccine 0
Influenza Vaccines 0
Pneumococcal Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Commonwealth of Australia CC BY-NC-ND.

Auteurs

Harunor Rashid (H)

National Centre for Immunisation Research and Surveillance (NCIRS), Kids Research, The Children's Hospital at Westmead, Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia.

Aditi Dey (A)

National Centre for Immunisation Research and Surveillance (NCIRS), Kids Research, The Children's Hospital at Westmead, Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia.

Ramesh Manocha (R)

Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia; Healthed, PO Box 500, Burwood, New South Wales, Australia.

Mohamed Tashani (M)

National Centre for Immunisation Research and Surveillance (NCIRS), Kids Research, The Children's Hospital at Westmead, Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia.

Kristine Macartney (K)

National Centre for Immunisation Research and Surveillance (NCIRS), Kids Research, The Children's Hospital at Westmead, Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia.

Frank Beard (F)

National Centre for Immunisation Research and Surveillance (NCIRS), Kids Research, The Children's Hospital at Westmead, Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH